Currently Viewing:
Newsroom
Currently Reading
The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System
December 15, 2018 – David Bai, PharmD
Osteoporosis Working Group Creates Recommendations for Economic Evaluations
December 15, 2018 – Allison Inserro
Federal Judge Strikes Down Affordable Care Act
December 15, 2018 – Allison Inserro and Mary Caffrey
Osteoporosis Screening Strategies Don't Identify Younger Women at Risk
December 14, 2018 – Allison Inserro
Study Determines Why Patients With HIV Have Higher Rates of Cancer
December 14, 2018 – Alison Rodriguez
Sofosbuvir-Based Therapy Safe in Patients With HCV and Certain Cancers
December 14, 2018 – Samantha DiGrande
Gender Differences Found in COPD Hospitalizations and In-Hospital Deaths
December 14, 2018 – Alison Rodriguez
Nontuberculous Mycobacterial Lung Disease Doubled the Risk of Death in a Managed Care Population
December 14, 2018 – Jackie Syrop
What We're Reading: Court Trims Birth Control Rule; Guns as Public Health Issue; California Lenient Toward Doctors
December 14, 2018 – AJMC Staff

Launch of Highly Efficacious HIV, Tuberculosis, and Malaria Vaccines Unlikely, Study Says

Jaime Rosenberg
Researchers determined that the current drug pipeline is unlikely to produce any highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.
With ambitious targets for ending the HIV and other infectious disease epidemics, prevention efforts are crucial for gaining hold of the diseases. However, the vaccines needed to combat these infectious diseases are not likely to be developed, according to a new study.

Analyzing vaccine candidates and other products in the research and development pipeline, researchers determined that the current pipeline is unlikely to produce highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.

The reason, according to the researchers, is lack of funding. Since 2008, annual funding for product development for these diseases has been $3 billion. However, this figure is at least $1.5 billion to $2.8 billion short of what’s needed.
“Closing this large financial gap will require a major effort to mobilize new resources from across the public, philanthropic, and private sectors,” wrote the researchers. “High-income governments have been the most important source to date for financing product development for neglected diseases, but they are arguably under-investing in such research given the very large health, social, and economic returns to investment.”

To determine future results based on current funding, the researchers conducted a pipeline portfolio review of 538 candidate products for 35 neglected diseases to estimate the costs of moving each product through the pipeline and the likelihood of a product launching. Products included drugs, vaccines, diagnostics, and multipurpose prevention technologies. Stages of development ranged from preclinical trials to phase 3 trials.

Researchers observed that 3 diseases dominated the pipeline: malaria (109 candidates), HIV/AIDS (99 candidates), and tuberculosis (98 candidates).

A cost analysis showed that, in order to move all 538 candidates through the pipeline, it would cost approximately $16.3 billion over 10 to 12 years. More than half (55%) of the cost would be attributable to phase 3 trials, one-third (33%) would be for phase 2 trials, 9% would be for preclinical development, and 4% would be for phase 1 trials. Vaccines would account for more than half of the cost (55%).

The researchers estimated that 128 products would make it to launch, two-thirds of which would be for HIV, tuberculosis, and malaria. However, launches of vaccines for the 3 diseases would be unlikely, according to the researchers.

The researchers also identified 18 high-priority “missing” products—products that are unlikely to be launched that are of particular need. These products include highly efficacious vaccines against HIV, tuberculosis, malaria, and hepatitis C. The total cost for launching these 18 products ranges from $13.6 billion to $21.8 billion over 10 to 12 years, depending on the complexity of the products.

“The model shows us where the current pipeline is most robust and where it is lacking,” Gavin Yamey, professor of global health and public policy and director of the Center for Policy Impact in Global Health, Duke Global Health Institute, said in a statement. “For global health advocates, this is a broad picture of what pieces we are likely to still be missing, and where we can direct priorities in funding and product development.”

Reference:

Young Ruth, Bekele T, Gunn A, et al. Developing new technologies for neglectied diseases: a pipeline portfolio review and cost model [published August 22, 2018]. Gates Open Res. doi: 10.12688/gatesopenres.12817.2.

Related Articles

Long-Term Analysis Highlights Half Trillion Dollars Spent on HIV/AIDS
Phase 1 Trial Will Test Safety of Vaccine for HIV Prevention
HIV Vaccine Candidate Proves Safe, Induces Immune Response in Healthy Adults, Monkeys
Urgent Change in Approach to HIV Pandemic Is Needed, Report Says
Between 1997 and 2015, Viral Suppression Rates Nearly Tripled in People Living With HIV
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!